Table 3

Activity, efficacy and effectiveness of FIr-B/FOx regimen according to KRAS genotype

c.35 G>A

KRAS mutant

other

KRAS mutant

KRAS wild-type


Intent-to-treat

analysis

Intent-to-treat

analysis

Intent-to-treat

analysis


Number

%

Number

%

Number

%


Enrolled pts

15

100

13

100

31

100

Evaluable pts

14

93

13

100

30

97

Objective response

10

71 (CI ± 26)

8

61 (CI ± 26)

27

90 (CI ± 11)

partial response

9

64

8

61

23

76

complete response

1

7

-

-

4

13

Stable disease

3

21

2

15

2

7

Progressive disease

1

7

3

23

1

3

Median PFS, months

9

12

14

range

1+-60+

3-37

1+-69+

progression events

10

67

12

92

25

81

Median OS, months

14

39

38

range

1+-60+

8-59+

1+-69+

deaths

10

67

8

61.5

17

55

Liver metastasectomies

2

5

11

number/overall pts

2/15

13

5/13

38

11/31

35

number/Pts with liver metastases

2/12

17

5/8

62.5

11/19

58

number/Pts with L-L metastases

2/6

33

5/7

71

10/12

83

Pathologic complete responses

-

-

2

40

-

-


L-L, liver-limited; OS, overall survival; PFS, progression-free survival; pts, patients.

Bruera et al. BMC Medicine 2013 11:59   doi:10.1186/1741-7015-11-59

Open Data